Lung Cancer

Cost-effectiveness of Nivolumab in Patients With NSCLC in the United States

August 24th 2021, 1:00pm


This article presents a cost-effectiveness analysis of nivolumab vs docetaxel from the US payer perspective in non–small cell lung cancer (NSCLC) based on randomized phase 3 studies with a minimum 5 years of follow-up.

An Inside Look at Disparities in Lung Cancer Care for At-Risk Populations

August 1st 2021, 1:00pm


On World Lung Cancer Day, we explore current guidelines for lung cancer screening in the United States, implications of the COVID-19 pandemic, and disparities in mortality and access to care by race and socioeconomic status.

Insights on Small-Cell Lung Cancer NCCN Guidelines

April 4th 2021, 4:00pm


Kathryn Gold, MD, medical oncologist and associate professor of medicine at UC San Diego, who is a member of the NCCN guidelines panel for small-cell lung cancer, gives insight into the guidelines and the importance of frequent updates.

FDA Approves Osimertinib for Adjuvant Treatment of Early-Stage EGFR-Mutated NSCLC

February 16th 2021, 7:00pm


The new indication for osimertinib (Tagrisso) marks the first FDA approval of an adjuvant treatment for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations.

Certain NSCLC Patients Are More Likely to Respond to Immunotherapy, Study Results Show

February 16th 2021, 6:30pm


A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy.

Possible Treatment Identified for Aggressive NSCLC Subset

February 16th 2021, 6:00pm


Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have KRAS and LKB1 mutations.

Lung Cancer Screenings Fall, Biopsy Rates Rise During COVID-19

February 15th 2021, 10:15pm


Deferred low-dose computed tomography lung cancer screening during the coronavirus disease 2019 (COVID-19) pandemic has worsened outcomes for patients with lung cancer, a new study found.

FDA Grants Tiragolumab Breakthrough Therapy Designation for PD-L1–High NSCLC

February 15th 2021, 6:30pm


Genentech's tiragolumab, a novel immunotherapy for non-small cell lung cancer with PD-L1 expression, is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation.

What We’re Reading: More Americans Vaccinated Than Infected; US Funds Rapid OTC COVID-19 Tests; Breast Most Common Cancer Worldwide

February 2nd 2021, 3:33pm


More Americans have received at least 1 dose of a coronavirus disease 2019 (COVID-19) vaccine than have tested positive for the virus; Biden administration funds mass production of a rapid over-the-counter COVID-19 test; breast cancer surpasses lung cancer as most common cancer worldwide.

First-line Nivolumab and Ipilimumab Plus Chemotherapy Improves OS in NSCLC

January 23rd 2021, 3:30pm


Recently published results show that adding a limited course of chemotherapy to nivolumab plus ipilimumab in the first-line setting for non-small cell lung cancer is effective and tolerable.